Boehringer Ingelheim ’s BI 425809 for Cognitive Impairment Associated with Schizophrenia Receives FDA Breakthrough Therapy Designation

RIDGEFIELD, CT, May 24, 2021– Boehringer Ingelheim today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for BI 425809 for the treatment of Cognitive Impairment Associated with...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials